TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure

On January8, 2018, TESARO,Inc. (“TESARO” or the “Company”) is attending the 36th AnnualJ.P. Morgan Healthcare Conference in San Francisco, California. During meetings with investors, the Company expects to utilize a presentation containing a general business update, including with respect to the ZEJULA® commercial launch. The presentation includes, among other things, various updated information with respect to ZEJULA’s U.S. market share among ovarian cancer patients and in the U.S. PARP market generally, and the expected range of ZEJULA net revenues for the quarter and fiscal year ended December31, 2017. A copy of the presentation is attached to this current report as Exhibit99.1 and is incorporated herein by reference.

The information contained in this report, including Exhibit99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section. Furthermore, such information shall not be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

To the extent that the information in this report, including Exhibit99.1, are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this report, including Exhibit 99.1, include, among others, statements regarding our expected ZEJULA net revenues for the quarter and fiscal year ended December31, 2017, the potential size of the current and future market opportunities for our various products and product candidates and our various assumptions related thereto, the expected trends in duration of treatment with ZEJULA, the design and expected timing of initiation and data from our various planned niraparib, TSR-042, TSR-033, TSR-022, combination studies, and other ongoing clinical trials, and the details of our key near-term value drivers. Forward-looking statements in this report, including Exhibit 99.1, involve substantial risks and uncertainties that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the results of the final audit of our consolidated financial statements for the year ended December31, 2017, risks related to competition, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from clinical trials, uncertainties surrounding our ongoing discussions with and potential actions by regulatory authorities, risks related to manufacturing and supply, risks related to intellectual property, and other matters that could affect the availability or commercial potential of our products and product candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO’s Annual Report on Form10-K for the year ended December31, 2016 and its Quarterly Report on Form10-Q for the quarter ended September30, 2017.

Section 9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


TESARO, Inc. Exhibit
EX-99.1 2 a18-2384_1ex99d1.htm EX-99.1 Exhibit 99.1 January 2018 Investor Meetings   Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO,…
To view the full exhibit click here

About TESARO,Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.